SS-31 (Elamipretide)

What is SS-31 (Elamipretide)?

SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide and the most clinically advanced mitochondrial peptide by a wide margin. After two decades of research it reached a real milestone: in September 2025 the FDA granted accelerated approval to elamipretide, under the brand name Forzinity, for Barth syndrome, a rare inherited mitochondrial disorder. That makes it the first mitochondria-targeted therapy ever approved.

How SS-31 (Elamipretide) works

SS-31 is engineered to embed itself in the inner mitochondrial membrane, where it binds and stabilizes cardiolipin. Cardiolipin is the phospholipid that organizes the electron transport chain, the machinery that makes cellular energy. By stabilizing it, SS-31 helps preserve mitochondrial structure and function and reduces the oxidative damage that comes from leaky energy production. The targeting is highly specific to the mitochondrial membrane.

What the research shows

This is the rare mitochondrial peptide with a genuine human clinical program: numerous phase 2 and phase 3 trials across conditions, with systematic analyses of both successes and failures. The results are genuinely mixed. Preclinical models showed benefit in many settings, but several human trials, including in heart failure and primary mitochondrial myopathy, did not meet their primary endpoints. The success that carried it to approval was in Barth syndrome. So the honest read is a serious, well-studied drug with real but narrow proven benefit, not a broad anti-aging tool.

Dosage and how it is used

Clinical trial dosing has been by subcutaneous injection under medical supervision, and the approved product has its own defined regimen for its indication. There is no standardized self-use protocol for general mitochondrial health, and using it that way is outside the evidence.

→ How to reconstitute SS-31 (Elamipretide): calculator, units to draw & storage

Side effects and safety

In its trials, injection-site reactions were among the more common issues, and the overall program generated a substantial human safety dataset, which is unusual for compounds in this library. Approval for a specific rare disease does not mean it is validated or appropriate for general performance or longevity use, and it should be treated as a prescription medicine.

• Research depth: extensive human trials; FDA-approved (Forzinity) for Barth syndrome in 2025.
• Many trials in other conditions missed endpoints; proven benefit is narrow.
• Approved for a specific rare disease; general self-use is off-label. Verify status independently.

Frequently asked questions

References

• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci (MDPI), 2025.
• Mitochondrial protein interaction landscape of SS-31. PNAS, 2020.